HSIC · NASDAQ · STOCK
Henry Schein (HSIC) Stock Analysis
$89.80
52W $61.95 – $92.18
63/100
$10.35B
26.3
0.81
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is HSIC Bullish or Bearish?
Bullish.
Innellis AI committee rates Henry Schein (HSIC) Buy with a composite score of 63/100
, based on 6 analysts with 67% agreement.
Last updated September 05, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +12.31 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -7.69 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The primary driver is news sentiment is positive (+0.71 across 7 articles, 14d). The main limiting factor is p/e of 25.0 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull & Bear Case
Bull Case
- 4 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- News sentiment is positive (+0.71 across 7 articles, 14d) — News
Bear Case
- P/E of 25.0 is moderate-to-rich — Value
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of September 05, 2026
Overall Committee Score
63/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 22%
of 192 Healthcare peers
Value Analyst
neutral
48
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− P/E of 25.0 is moderate-to-rich
Growth Analyst
neutral
52
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ 4 consecutive earnings beats -- consistent execution
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Risk Analyst
bullish
70
/ 100 · Moderate confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
81
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.71 across 7 articles, 14d)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 3059.07)
Investment Thesis Evolution
Committee score moved marginally from 62.7 to 62.7.
Comparing 2026-09-04 to 2026-09-05 (1 day apart).
Technical Analysis
RSI (14)
63.4
Neutral
MACD Histogram
-0.097
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Support
$73.09
Resistance
$92.18
Bollinger %B
0.91
Inside Bands
Price vs Moving Averages
EMA 9
$89.84
Below
EMA 21
$89.14
Above
EMA 50
$86.78
Above
EMA 200
$79.65
Above
Fundamental Analysis
Valuation
50
Growth
61
Profitability
34
Financial Health
54
Cash Flow
70
Valuation
P/E Ratio
26.3×
P/B Ratio
3.27×
PEG Ratio
2.58
Dividend Yield
0.00%
52W High
$92.18
52W Low
$61.95
Quality & Growth
ROE
1226.5%
ROA
354.9%
Gross Margin
3031.2%
Operating Margin
569.0%
Revenue Growth YoY
—
Debt / Equity
1.21
AI Fundamental Assessment
P/E ratio of 26.3 (moderate relative to a 15-40x range); Price-to-book of 3.3x; PEG ratio of 2.6 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 12.3%; Return on assets of 3.5%; Net margin of 3.0%; Gross margin of 30.3%; Current ratio of 1.32 (tight short-term liquidity); Debt-to-equity of 1.21; Free cash flow per share is positive (4.75); Most recent quarter beat estimates by 0.7%; 4 consecutive earnings beats; EPS growth decelerating (-1.5% -> -3.8% QoQ); Average YoY EPS growth of 15.4%; Analyst estimates falling over recent quarters
Get the Full HSIC Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →